Ratings by Rothschild Redburn (Jamie Clark)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/8/2026 | Tempus AI Inc | TEM | New Coverage | Neutral (N/A) |
64.66 (64.72) |
0.09% | Details | |
| 9/8/2026 | Natera | NTRA | New Coverage | Buy (N/A) |
327.67 (393.44) |
20.07% | Details | |
| 9/8/2026 | Guardant Health | GH | New Coverage | Buy (N/A) |
161.04 (158.60) |
-1.52% | Details | |
| 2/17/2026 | ICON plc | ICLR | Downgrade | Neutral (Buy) |
80.08 (170.18) |
112.51% | Details | |
| 11/21/2025 | Certara Inc. | CERT | New Coverage | Buy (N/A) |
8.29 (9.37) |
13.03% | Details | |
| 9/15/2025 | West Pharmaceutical | WST | New Coverage | Buy (N/A) |
263.74 (384.02) |
45.61% | Details | |
| 9/3/2025 | Iconix Brand | ICON | Upgrade | Buy (Neutral) |
1.92 (1.03) |
-46.35% | Details | |
| 9/3/2025 | Medpace | MEDP | Downgrade | Neutral (Buy) |
475.51 (618.47) |
30.06% | Details | |
| 9/3/2025 | ICON plc | ICLR | Upgrade | Buy (Neutral) |
177.94 (80.08) |
-55% | Details | |
| 5/23/2025 | Charles River Labs | CRL | Upgrade | Buy (Neutral) |
134.98 (300.15) |
122.37% | Details | |
| 4/2/2025 | Quest Diagnostics | DGX | New Coverage | Buy (N/A) |
169.20 (235.00) |
38.89% | Details | |
| 4/2/2025 | Laboratory Corporation of America | LH | New Coverage | Buy (N/A) |
232.74 (317.95) |
36.61% | Details | |
| 3/3/2025 | Charles River Labs | CRL | Upgrade | Neutral (Sell) |
164.88 (134.98) |
-18.13% | Details |
